MRGBP, also known as C20orf20, is a subunit of the NuA4 histone acetyltransferase complex involved in transcriptional activation by acetylation of nucleosomal histones H4 and H2A [5,6]. It is associated with multiple biological processes and disease-related pathways, such as the DKK1/Wnt/β-catenin and NF-kB/p65 pathways [1]. It is widely involved in physiological and pathological processes, and its study through genetic models can help understand its functions.

In various cancers, functional studies have shown its oncogenic role. In colorectal cancer, MRGBP promotes cell proliferation, migration, invasion, epithelial-mesenchymal transition (EMT), and xenograft tumor growth via DKK1/Wnt/β-catenin and NF-kB/p65 pathways, and high expression correlates with poorer survival [1]. In pancreatic ductal adenocarcinoma, knockdown of MRGBP attenuates cell proliferation, migration, and invasion, while overexpression has the opposite effect [4]. In head and neck squamous cell carcinoma, high MRGBP expression is an independent risk factor for overall survival (OS) [2]. In hepatocellular carcinoma, high MRGBP expression is associated with a higher T stage, pathologic stage, and worse OS, and is correlated with immune cell infiltration [3].

In conclusion, MRGBP plays an important oncogenic role in multiple cancers, affecting processes like cell proliferation, migration, and invasion. Studies on MRGBP, especially through functional loss-of-function experiments in cancer models, contribute to understanding cancer development mechanisms, highlighting its potential as a prognostic biomarker and therapeutic target in cancer research.